|5-fluorouracil treatment relevance (5-FU) - DPYD1|
5-Fluorouracil (5-FU) is widely and successfully used for the treatment of solid tumors. The drug is rapidly metabolized in the liver. The initial and rate-limiting enzyme of the detoxification pathway is dihydropyrimidine dehydrogenase (DPD). Only a small portion of the administered drug becomes active in the targeted tumor tissue. About 3-5% of patients treated with 5-FU will not adequately metabolize the drug and as quickly as anticipated, and will accumulate high levels of the drug. In most of these cases a variation in the intron 14 splice site (IVS14+1 G>A) of the DPD-encoding gene DPYD is responsible. Heterozygous patients should receive lower doses of 5-FU, while homozygous patients should be treated with alternative chemotherapeutics in order to avoid life-threatening toxic side effects.
|Գին՝ 20 000 AMD|